Lisata Therapeutics Inc. Common Stock (LSTA)

FairStock Score: 47/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a Graham-style bargain hunter: I want proven earnings, durable assets, and a margin of safety. Lisata offers none of those today. It is a 21-employee clinical-stage biotech developing certepetide for solid tumors, with no approved product and no meaningful commercial revenue. In fiscal 2025, the year ended 2025-12-31, revenue was $170,000 and net loss was $16.6 million, or $1.91 per diluted share. In fiscal 2024, the year ended 2024-12-31, revenue was $1.0 million and net loss was $20.0 million, or $2.40 per diluted share. In fiscal 2023, the year ended 2023-12-31, net loss was $20.8 million, or $2.58 per diluted share. The most recent filed quarter, fiscal Q2 2026 ended 2026-06-30, showed a $2.9 million net loss and a $0.32 diluted loss per share. Free cash flow is negative $12.3 million trailing twelve months, and the FairStock-calculated FCF yield is -126.6%. At the close on 2026-10-13, price was $1.08 and market cap $9.7 million; FairStock P/B is 1.20 and P/E is -0.66. FairStock-calculated ROE is -101.66% and ROCE is -56.74%. The Altman Z-Score of -70.75 and Piotroski F-Score of 3/9 suggest financial fragility. There is no moat: the value rests entirely on clinical trial outcomes. Growth is not commercial; it is a hope that a pipeline candidate works. That may be a lottery ticket, but it is not a Buffett-style business. Without revenue, profits, or cash generation, the low price is not the same as cheap.

In plain English: Lisata Therapeutics is a small clinical-stage biotech working on a drug for solid tumors. The business looks weak financially: it has almost no revenue, loses millions each year, and burns cash. Its $1.08 stock price may look low, but because there are no profits or meaningful sales, it is hard to call it cheap based on the numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer